SXTP

60 Degrees Pharmaceuticals Inc

0.9400

Oct 30 • 3:59 PM ET -0.0075 (-0.79%)

0.9118

Aftermarket • 6:53 PM ET -0.0282 (-3.00%)

Healthcare Biotechnology USA Nano NASD

Peers: IMRN TRAW ACXP SPRO COCP VALN CTXR ARMP AVIR NNVC

Scroll to Statements

Index	-
Market Cap	3.31M
Enterprise Value	11.92M
Income	-8.62M
Sales	1.21M
Book/sh	-2.61
Cash/sh	0.29
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	5
IPO	Jul 12, 2023

P/E	-
Forward P/E	-
PEG	-
P/S	2.74
P/B	-
P/C	3.25
P/FCF	-
EV/EBITDA	-
EV/Sales	9.85
Quick Ratio	1.78
Current Ratio	2.32
Debt/Eq	0.06
LT Debt/Eq	0.06
Option/Short	No / Yes

EPS (ttm)	-6.19
EPS next Y	-
EPS next Q	-0.61
EPS this Y	73.06%
EPS next Y	-
EPS next 5Y	-
EPS past 3/5Y	64.19% 37.74%
Sales past 3/5Y	40.21% -11.18%
EPS Y/Y TTM	86.32%
Sales Y/Y TTM	24.77%
EPS Q/Q	81.96%
Sales Q/Q	-32.47%
Earnings	Aug 14 BMO
EPS/Sales Surpr.	-22.45% 12.38%

Insider Own	24.84%
Insider Trans	0.85%
Inst Own	13.51%
Inst Trans	5.00%
ROA	-191.39%
ROE	-321.29%
ROIC	-293.13%
Gross Margin	26.32%
Oper. Margin	-708.59%
Profit Margin	-709.19%
SMA20	0.18%
SMA50	-7.00%
SMA200	-46.99%
Trades

Shs Outstand	2.66M
Shs Float	2.64M
Short Float	5.13%
Short Ratio	0.33
Short Interest	0.14M
52W High	8.62 -89.10%
52W Low	0.59 59.86%
Volatility	24.15% 15.89%
ATR (14)	0.14
RSI (14)	48.69
Beta	2.42
Rel Volume	0.18
Avg Volume	407.84K
Volume	73,529

Perf Week	8.03%
Perf Month	-24.80%
Perf Quarter	-18.97%
Perf Half Y	-43.37%
Perf YTD	-53.77%
Perf Year	-82.97%
Perf 3Y	-99.35%
Perf 5Y	-
Perf 10Y	-
Recom	2.00
Target Price	3.70
Prev Close	0.95
Price	0.94
Change %	-0.79%

Oct-28-26 08:30AM	60 Degrees Pharmaceuticals Announces Partnership with The University of Southern Mississippi to Evaluate Castanospermine in Nonclinical Models of Alpha-Gal Syndrome (GlobeNewswire) +14.46%
Oct-27-26 08:06AM	60 Degrees Pharmaceuticals Announces Clinical Improvement and Negative PCR Results in All Completed Expanded Access Babesiosis Study Patients (GlobeNewswire) -14.74%
Oct-06-26 10:44AM	60 Degrees Pharmaceuticals Sets January 2027 Babesiosis Data Readout and Plans FDA Pre-sNDA Meeting (InvestorsHub) -22.92%
08:10AM	60 Degrees Pharmaceuticals Plans January 2027 Hospitalized Babesiosis Data Readout; Will Seek Pre-sNDA Meeting with FDA (GlobeNewswire)
Oct-01-26 08:03AM	60 Degrees Pharmaceuticals Announces Date for Hospitalized Babesiosis Study Interim Data Release and Key Opinion Leader Webinar (GlobeNewswire) -6.02%
08:04AM	Loading…
Sep-03-26 08:04AM	60 Degrees Pharmaceuticals Announces Participation in H.C. Wainwright 28th Annual Global Investment Conference (GlobeNewswire)
Aug-14-26 03:47PM	60 Degrees Pharmaceuticals Announces Second Quarter 2026 Results (GlobeNewswire)
Jul-30-26 02:23PM	60 Degrees Pharmaceuticals, Inc. Announces Private Placement Priced At-the-Market Under Nasdaq Rules (GlobeNewswire) -16.11%
Jul-29-26 04:03PM	60 Degrees Pharmaceuticals Announces Minimum Enrollment Achieved in Hospitalized Babesiosis Study; Interim Data Readout Planned by October 6, 2026 (GlobeNewswire)
Jul-08-26 08:01AM	60 Degrees Pharmaceuticals Announces Exclusive Option Agreement with Florida State University to Advance Castanospermine for Tick-Borne Diseases (GlobeNewswire)
Jul-01-26 08:02AM	60 Degrees Pharmaceuticals Announces Positive Recommendation from Data Safety Monitoring Board for B-FREE Phase 2 Study of Tafenoquine for Treatment of Chronic Babesiosis Patients with Severe Fatigue (GlobeNewswire)
Jun-11-26 08:03AM	60 Degrees Pharmaceuticals Signs Exclusive Patent License Agreement with Florida State University for Non-Prescription Use of Australian Chestnut Extract as a Botanical Supplement (GlobeNewswire)
May-26-26 08:02AM	60 Degrees Pharmaceuticals Announces Early Enrollment of First Seasonal Patient in Clinical Trial of Tafenoquine for Patients Hospitalized with Babesiosis (GlobeNewswire)
May-15-26 08:42AM	60 Degrees Pharmaceuticals Announces First Quarter 2026 Results (GlobeNewswire)
Apr-15-26 08:02AM	60 Degrees Pharma Announces ARAKODA (tafenoquine) for Malaria Prevention is Now Available on Runway Health Travel Website (GlobeNewswire) -11.71%
07:01AM	Loading…
Mar-31-26 07:01AM	60 Degrees Pharmaceuticals Announces 2025 Annual Results (GlobeNewswire) +15.89%
Mar-18-26 08:01AM	60 Degrees Pharmaceuticals Files New Dietary Ingredient Notification (NDIN) with FDA for Australian Chestnut Extract (GlobeNewswire) -5.78%
Mar-11-26 07:24AM	60 Degrees Pharmaceuticals Announces All Patients Cured of Babesiosis After Tafenoquine Treatment in Expanded Use Clinical Trial (GlobeNewswire) +71.28%
Feb-24-26 01:10PM	60 Degrees Pharmaceuticals (SXTP) Partners With GoodRx to Expand Access to ARAKODA (Insider Monkey)
Feb-02-26 08:01AM	60 Degrees Pharmaceuticals Expands Access to ARAKODA with GoodRx Partnership (GlobeNewswire) -12.29%
Jan-28-26 08:01AM	60 Degrees Pharmaceuticals Exercises License Option with Florida State University for Large-Scale Purification of Castanospermine for Non-Rx Use (GlobeNewswire) +7.88%
Jan-22-26 11:02AM	60 Degrees Pharmaceuticals Soars After Runway Health Partnership (Benzinga) +152.00%
08:01AM	60 Degrees Pharmaceuticals Announces Partnership with Runway Health to Provide International Travelers Direct Access to ARAKODA for Malaria Prevention (GlobeNewswire)
Jan-15-26 08:01AM	60 Degrees Pharmaceuticals, Inc. Announces Approval of Reverse Stock Split Ratio (GlobeNewswire)
Dec-30-25 08:10AM	60 Degrees announces detection of babesia infection in 24% of patients in study (TipRanks) -8.57%
Dec-29-25 08:01AM	60 Degrees Pharmaceuticals Announces Detection of Babesia Infection in 24 Percent of Patients Presenting with Chronic Fatigue in Peer-Reviewed, Sponsored Study at NC State (GlobeNewswire) -20.55%
Dec-23-25 09:55AM	Here's Why 60 Degrees Pharmaceuticals Inc. (SXTP) Looks Ripe for Bottom Fishing (Zacks) -6.20%
Dec-11-25 08:01AM	60 Degrees Pharmaceuticals Announces Expansion of ARAKODA Sales and Marketing in 2026 (GlobeNewswire) -7.02%
Nov-22-25 08:15AM	60 Degrees announces central site for B-FREE study open for patient enrollment (TipRanks)
Nov-21-25 08:01AM	60 Degrees Pharmaceuticals Announces Clinical Site Now Open for Patient Enrollment for the B-FREE Chronic Babesiosis Study at Mount Sinai Icahn School of Medicine (GlobeNewswire)
01:51PM	Loading…
Nov-13-25 01:51PM	60 Degrees Pharmaceuticals Announces Third Quarter 2025 Results (GlobeNewswire)
Oct-15-25 07:14AM	60 Degrees Pharmaceuticals Announces No Detection of Babesia Infection in First Patient Following Treatment with Tafenoquine in Relapsing Babesiosis Study (GlobeNewswire) -14.17%
Oct-09-25 07:04AM	60 Degrees Pharmaceuticals Unveils Name of Chronic Babesiosis Clinical Trial: B-FREE Chronic Babesiosis Study (GlobeNewswire) +5.48%
Sep-03-25 08:02AM	60 Degrees Pharmaceuticals Live Webcast Link and New Date for Presentation at H.C. Wainwright 27th Annual Global Investment Conference (GlobeNewswire)
Aug-21-25 08:31AM	60 Degrees Pharmaceuticals to Present at H.C. Wainwright 27th Annual Global Investment Conference (GlobeNewswire)
Aug-20-25 07:38AM	60 Degrees to commence Phase II babesiosis trial at Mount Sinai (Clinical Trials Arena)
Aug-19-25 08:54AM	60 Degrees Pharmaceuticals Selects Icahn School of Medicine at Mount Sinai as Central Clinical Trial Site for Phase II Study to Evaluate Tafenoquine for Chronic Babesiosis (GlobeNewswire)
Aug-13-25 04:14PM	60 Degrees Pharmaceuticals Announces Second Quarter 2025 Results (GlobeNewswire)
Aug-04-25 05:30PM	Ardelyx (ARDX) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
Jul-17-25 08:01AM	60 Degrees Pharmaceuticals and Tulane University Sign Research Agreement to Study Tafenoquine Against Lyme and Bartonella Bacteria (GlobeNewswire) -7.93%
Jul-16-25 04:01PM	60 Degrees Pharmaceuticals Announces Closing of up to $10 Million Public Offering (GlobeNewswire) -6.29%
Jul-15-25 09:10AM	60 Degrees Pharmaceuticals Announces Pricing of Up to $10 Million Public Offering (GlobeNewswire) -19.17%
07:01AM	60 Degrees Pharmaceuticals Defines Potential Human Babesiosis Market Size for ARAKODA (tafenoquine): Annual Max TAM, Sales of $245 Million; Cumulative through Patent Expiration, $1.1 Billion (GlobeNewswire)
Jul-14-25 04:01PM	60 Degrees Pharmaceuticals to Submit MUMS (Minor Use/Minor Species) Designation Request to FDA for Tafenoquine for Acute Canine Babesiosis in 2025 (GlobeNewswire) -14.09%
Jun-04-25 08:56AM	60 Degrees Pharmaceuticals Expands Options for Malaria Prevention with Introduction of ARAKODA (tafenoquine) 8-Count Bottle Format (GlobeNewswire)
08:55AM	60 Degrees announces results from an insurance claims analysis on babesiosis (TipRanks)
Jun-03-25 08:49AM	Babesiosis Incidence in U.S. 10x Higher Than CDC Estimates, According to Insurance Claims Study Commissioned by 60 Degrees Pharmaceuticals (GlobeNewswire)
May-15-25 04:31PM	60 Degrees Pharmaceuticals Announces First Quarter 2025 Results (GlobeNewswire) +14.88%
May-08-25 05:10PM	Harrow (HROW) Reports Q1 Loss, Lags Revenue Estimates (Zacks) +5.75%
Apr-22-25 08:44AM	Babesiosis Disease Burden in United States is Substantially Higher Than Official Estimates, According to Preliminary Results of 60 Degrees Pharma Survey (GlobeNewswire) -15.51%
Apr-10-25 09:24AM	Why 60 Degrees Pharmaceuticals, Inc. (SXTP) Went Down On Thursday? (Insider Monkey) +24.00%
08:31AM	Geoff Dow, PhD, Infectious Disease Product Development Expert, to Discuss Babesiosis at Healing Lyme Summit, April 15-21 (GlobeNewswire)
Apr-08-25 08:31AM	Sixty Degrees Pharmaceuticals Announces Patent License Agreement to Advance Development of Tafenoquine for Babesiosis Treatment and Prevention with Yale School of Medicine and Yale School of Public Health (GlobeNewswire) +59.59%
Mar-28-25 06:59AM	60 Degrees Pharmaceuticals Announces 2024 Annual Results (GlobeNewswire)
Feb-21-25 09:00AM	60 Degrees Pharmaceuticals and Fathom Holdings Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV (ACCESSWIRE)
Feb-20-25 10:36AM	60 Degrees Pharmaceuticals, Inc. Announces 1:5 Reverse Stock Split (GlobeNewswire) -10.92%
Feb-11-25 12:59PM	Sixty Degrees Pharmaceuticals to Ensure Continuity of Tafenoquine Supply in U.S. by Importing Limited Quantity of KODATEF (GlobeNewswire)
Feb-06-25 02:07PM	60 Degrees Pharma Announces Closing of $1.075 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules (GlobeNewswire)
Feb-05-25 09:22AM	60 Degrees Pharma Announces $1.075 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules (GlobeNewswire) -14.29%
Feb-03-25 08:30AM	RedChip Launches RedChat: Revolutionary AI Chatbot for Small-Cap Stock Analysis (ACCESSWIRE) -14.65%
Jan-30-25 02:20PM	60 Degrees Pharma Announces Closing of $1.043 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules (GlobeNewswire) -24.53%
Jan-29-25 08:00AM	60 Degrees Pharma Announces $1.043 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules (GlobeNewswire) +37.52%
Jan-28-25 08:01AM	60 Degrees Pharma Announces IRB Approval of Phase II Study to Evaluate Tafenoquine for Chronic Babesiosis (GlobeNewswire) -11.01%
Jan-09-25 08:30AM	60 Degrees Pharmaceuticals enrolls first patient in tafenoquine study (TipRanks)
Jan-08-25 08:02AM	60 Degrees Pharmaceuticals Enrolls First Patient in Tafenoquine Expanded Access Clinical Study for Persistent (B. microti) Babesiosis (GlobeNewswire) -22.14%
Dec-24-24 09:05AM	60 Degrees, Tufts Medical Center announces patent license agreement (TipRanks) +13.79%
Dec-23-24 08:57AM	Sixty Degrees Pharmaceuticals and Tufts Medical Center Announce Patent License Agreement to Advance Development of Tafenoquine for Babesiosis Treatment and Prevention (GlobeNewswire) -7.94%
Dec-11-24 08:56AM	60 Degrees Pharmaceuticals Expands Tafenoquine Clinical Trial for Babesiosis to Brigham and Women's Hospital (GlobeNewswire) +13.33%
Dec-02-24 04:05PM	VSee Health and 60 Degrees Pharmaceuticals Interviews Aired on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV (ACCESS Newswire)
Nov-22-24 09:00AM	60 Degrees Pharmaceuticals and Can-Fite BioPharma Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV (ACCESSWIRE)
Nov-14-24 02:31PM	60 Degrees Pharmaceuticals Announces Third Quarter 2024 Results (GlobeNewswire)
Oct-03-24 09:02AM	60 Degrees Pharmaceuticals Inc. Announces ARAKODA Promotional Pilot in Advance of Expanded U.S. Launch (GlobeNewswire) -7.83%
Sep-06-24 08:59AM	60 Degrees Pharmaceuticals, Inc. Announces Closing of $4 Million Private Placement Priced At-the-Market Under Nasdaq Rules (GlobeNewswire) -5.56%
Sep-04-24 08:00AM	60 Degrees Pharmaceuticals, Inc. Announces $4 Million Private Placement Priced At-the-Market Under Nasdaq Rules (GlobeNewswire)
Aug-28-24 02:48PM	60 Degrees Pharmaceuticals, Inc. Regains Compliance with Nasdaq Listing Requirements (GlobeNewswire) -8.33%
Aug-14-24 11:01AM	60 Degrees Pharmaceuticals Announces Second Quarter 2024 Results (GlobeNewswire)
Aug-12-24 09:12AM	60 Degrees Pharma Provides University of Kentucky with Right of Reference to ARAKODA NDA in Support of SJ733 Phase IIb Study (GlobeNewswire) +44.69%
Aug-06-24 09:26AM	60 Degrees Pharmaceuticals, Inc. Announces 1:12 Reverse Stock Split (GlobeNewswire) -16.67%
Jul-25-24 09:02AM	60 Degrees Pharmaceuticals Awarded Contract with U.S. Army for ARAKODA Supply Chain Upgrade Support (GlobeNewswire) +6.40%
Jul-19-24 08:29AM	60 Degrees Pharmaceuticals Signs Clinical Trial Agreements With All Planned Trial Sites for Tafenoquine Babesiosis Study (GlobeNewswire) +10.16%
Jul-09-24 07:39AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday (InvestorPlace) +5.36%
06:31AM	60 Degrees Pharma Announces IRB Approval of Clinical Study of Tafenoquine for Treatment of Babesiosis in Immunocompromised Patients with Persistent Babesia microti Despite Prior Treatment (GlobeNewswire)
Jun-27-24 07:59AM	First Patient Enrolled in 60 Degrees Pharmaceuticals Clinical Trial of Tafenoquine for Babesiosis at Tufts Medical Center; First and Only Study of Its Kind (GlobeNewswire)
Jun-11-24 07:59AM	60 Degrees Pharmaceuticals Receives FDA Orphan Drug Designation for Tafenoquine for Treatment of Patients with Acute Babesiosis (GlobeNewswire)
Jun-06-24 07:38AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday (InvestorPlace) +20.67%
May-30-24 07:59AM	Enrollment in 60 Degrees Pharmaceuticals Clinical Trial of Tafenoquine for Babesiosis to Begin at Tufts Medical Center; First Study of Its Kind (GlobeNewswire) +5.38%
May-20-24 07:59AM	60 Degrees Pharmaceuticals Funds Babesia spp Testing in Chronic Fatigue Patient Samples in NC State College of Veterinary Medicine Study (GlobeNewswire) +24.06%
May-15-24 09:55PM	SXTP Stock Earnings: 60 Degrees Reported Results for Q1 2024 (InvestorPlace)
01:45PM	60 Degrees Pharmaceuticals Announces First Quarter 2024 Results (GlobeNewswire)
May-08-24 07:59AM	60 Degrees Pharmaceuticals Outlines Upcoming Clinical Trial of Tafenoquine in Babesiosis in Letter to Journal of Infectious Diseases (GlobeNewswire) +8.54%
May-02-24 07:59AM	60 Degrees Pharmaceuticals Receives FDA Comments on Tafenoquine-Babesiosis Clinical Trial Protocol; No Material Changes Required (GlobeNewswire)
Apr-03-24 07:58AM	60 Degrees Pharmaceuticals to Sponsor Pilot Study of Tafenoquine for Treatment of Canine Babesiosis (GlobeNewswire)
Mar-14-24 07:59AM	60 Degrees Pharmaceuticals Announces Communication from the FDA of Intention to Respond to Tafenoquine-Babesiosis Trial Protocol Submission in April, 2024 (GlobeNewswire) -7.30%
Feb-20-24 07:59AM	60 Degrees Pharmaceuticals to Sponsor Pre-Clinical Studies of Tafenoquine Use in Candida spp, Including Candida auris (GlobeNewswire)
Feb-08-24 07:59AM	60 Degrees Pharmaceuticals Appoints Kristen Landon as Chief Commercial Officer (GlobeNewswire)
Jan-31-24 12:00PM	WallachBeth Capital Announce Closing of 60 Degrees Pharmaceuticals $2.4 Million Public Offering (PR Newswire) -8.75%
11:15AM	60 Degrees Pharmaceuticals Announces Closing of $2.4 Million Public Offering (GlobeNewswire)
Jan-30-24 09:45AM	WallachBeth Capital Announces Pricing of 60 Degrees Pharmaceuticals $2.4 Million Public Offering (PR Newswire) -40.58%
09:00AM	60 Degrees Pharmaceuticals Announces Pricing of $2.4 Million Public Offering (GlobeNewswire)
Jan-22-24 07:59AM	60 Degrees Pharma Plans Pivotal Babesiosis Study with Tafenoquine Following Jan 17 FDA Meeting (GlobeNewswire) +19.97%

Show Previous News

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
DOW GEOFFREY S	President and CEO	Jun 12 '26	Buy	1.38	7,350	10,131	24,131	Jun 15 04:50 PM
DOW GEOFFREY S	President and CEO	Dec 15 '25	Buy	0.80	9,670	7,759	59,618	Dec 16 05:41 PM
DOW GEOFFREY S	President and CEO	Dec 10 '25	Buy	0.95	9,350	8,886	46,335	Dec 12 08:39 AM
DOW GEOFFREY S	President and CEO	Dec 11 '25	Buy	0.92	3,613	3,318	49,948	Dec 12 08:39 AM

60 Degrees Pharmaceuticals, Inc. develops medicines for the treatment and prevention of infectious diseases. Its product Arakoda helps in the prevention of malaria. The company was founded by Geoffrey Dow on September 9, 2010 and is headquartered in Washington, DC.

ChairmanDr. Geoffrey Stuart Dow Ph.D.

Chief Financial OfficerMr. Tyrone Miller

Chief Commercial OfficerMs. Kristen Landon

Chief Medical OfficerDr. Bryan Smith

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

SXTP

60 Degrees Pharmaceuticals Inc

Upgrade your Finviz experience